| |
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel CytoImmune's Puerto Rican clinical cell manufacturing facility’s success. Learn how your business can do the same. 
|
|
Today’s Big NewsFeb 6, 2024 |
| By Angus Liu Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease, with its massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect. |
|
|
|
By Annalee Armstrong,Zoey Becker With supply strains not letting up in the growing injectable obesity med market, Lilly looks to carve out manufacturing early for its oral candidate. |
By Fraiser Kansteiner Rumblings of a potential bidding war over cancer specialist MorphoSys have subsided as quickly as they arose after Novartis descended on the German biotech Monday with billions of dollars in cash. The move comes less than 24 hours after rumors of the M&A imbroglio surfaced in Reuters. |
By Gabrielle Masson Set the bar and then beat it; that's what Vertex Pharmaceuticals has just done with a next-gen cystic fibrosis treatment. |
By Kevin Dunleavy On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented figures that show Trikafta remains formidable. In the fourth quarter, Trikafta raked in $2.33 billion in sales, bringing its 2023 haul to $8.9 billion, a 16% increase from 2022. |
By Andrea Park Just as a rising tide is said to lift all boats, so too is a new FDA clearance expanding the reach of all of Boston Scientific’s WaveWriter spinal cord stimulation systems. |
By Fraiser Kansteiner AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs. |
By Conor Hale The notice includes the BrightView line of SPECT/CT scanners, with about 1,000 systems in use worldwide. The FDA said the heavy detector could land on the patient’s lower limbs, causing bruising and potential fractures. |
By Angus Liu If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep. |
By Max Bayer Kyverna is upping its planned IPO by about $100 million, now looking to net a little under $300 million. The cell therapy biotech has repriced its shares between $20 to $21. |
By Andrea Park While the original Dexcom One shared the same sensor as the G6 CGM, the Dexcom One+ system takes a step forward by incorporating the same sensor used in the G7 device. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
